, Tracking Stock Market Picks
Enter Symbol:
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

down 15.78 %

Acorda Therapeutics, Inc. (ACOR) rated Buy with price target $43 by Feltl & Co.

Posted on: Thursday,  Aug 1, 2013  11:25 AM ET by Feltl & Co.

Feltl & Co. rated Buy Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 08/01/2013, when the stock price was $37.63.
Since then, Acorda Therapeutics, Inc. has lost 15.79% as of 01/26/2016's recent price of $31.69.
If you would have followed this Feltl & Co.'s recommendation on ACOR, you would have lost 15.78% of your investment in 908 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

Feltl and Company's Research Department is focused on micro to small market capitalization companies that are not widely covered by other research firms. Our research universe is focused and organized around the sectors of Technology, HealthCare, and Leisure/Consumer. Feltl and Company holds its research department to very high standards, and strives to provide value- added investment ideas through sound fundamental analysis. Feltl and Company's Research Department includes six senior analysts and one associate analyst with many years of investment analysis experience. Although we are focused on, and committed to, companies in the Upper Midwest, our reach extends from coast to coast. About half of the companies we cover are headquartered outside our "backyard." Our analysts have significant industry experience and strive to know their companies inside and out. Through stringent analysis, they provide value by creating a disciplined application of company valuation, allowing our clients to make sound investment decisions.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/1/2013 11:25 AM Buy
37.63 43.00
as of 12/13/2013
1 Week down  -5.73 %
1 Month down  -11.10 %
3 Months down  -16.91 %
1 YTD down  -20.88 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy